http://www.pharmexec.com/pharmexec The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose of news and features from the world of pharma business and marketing. 2012-02-09T21:33:27Z http://www.pharmexec.com/pharmexec/Top+Feature/India-to-Double-Pharmaceutical-Exports-by-2014/ArticleStandard/Article/detail/757923?ref=25 With the $12-billion valued Indian pharma industry expected to grow at a CAGR of 16%, the Indian government plans to capitalize on the growth potential in an effort to beat the competition. 2012-02-02T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757923/India-flag-top-feature_flash.jpg XML http://www.pharmexec.com/pharmexec/Country+Reports/Of-Farms-Beaches-hellip-and-Generics/ArticleStandard/Article/detail/757970?ref=25 Brazilian industry is learning to spread its pharma manufacturing around more. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757970null XML http://www.pharmexec.com/pharmexec/E-Marketing/How-to-Choose-a-Medical-Animator/ArticleStandard/Article/detail/757963?ref=25 For a rendering to be effective, the right balance must be struck between captivating art and accurate science. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757963/med-animation-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757963null XML http://www.pharmexec.com/pharmexec/Noteworthy/Introducing-the-Chief-Patient-Officer/ArticleStandard/Article/detail/757969?ref=25 Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757969/Patient_120x90_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757969null XML http://www.pharmexec.com/pharmexec/Legal/Money-for-Nothing-Patents-for-Free/ArticleStandard/Article/detail/757958?ref=25 State tech transfer laws giving universities automatic ownership of employees' inventions represent a threat to pharma partnerships. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757958null XML http://www.pharmexec.com/pharmexec/Whitepaper/Increasing-Planning-Efficiency-in-Clinical-Develop/ArticleStandard/Article/detail/756937?ref=25 Discover how leading sponsors are increasing the accuracy of their cost forecasts and reducing budget variances for clinical trials to 5% or less. Drawing on research from the Tufts Center for the Study of Drug Development and others, this white paper presents current planning trends and challenges, as well as best practices that are helping sponsor companies compress timelines and reduce cost and risk in clinical development. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042012/756937null REMOTE http://www.pharmexec.com/pharmexec/Whitepaper/How-Customer-Analytics-Improve-Profitability/ArticleStandard/Article/detail/723161?ref=25 Customer analytics help the life sciences industry get a clearer focus on the effectiveness of its sales and marketing spending, understand current physician targeting data, forecast market demand and track social media sentiment. Read this white paper for a high-level overview of how analytics strengthens marketing strategies. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212011/723161null REMOTE http://www.pharmexec.com/pharmexec/Professional+Marketing/Best-to-Market/ArticleStandard/Article/detail/757966?ref=25 Pharm Exec's Brand of the Year: Abbott's Humira 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757966null XML http://www.pharmexec.com/pharmexec/Country+Reports/Eenie-Meenie-Minie-Biominas/ArticleStandard/Article/detail/757954?ref=25 Biominas helps foster the development of biotech-related businesses in Brazil. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757954null XML http://www.pharmexec.com/pharmexec/Global+Report/IndustryGovt-RampD-Support-So-Far-So-Good/ArticleStandard/Article/detail/757956?ref=25 The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757956null XML http://www.pharmexec.com/pharmexec/Country+Reports/Torrent-Indian-Success-Brazilian-Ways/ArticleStandard/Article/detail/757957?ref=25 Torrent's affiliate in Brazil has become the India-based company's biggest. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757957null XML http://www.pharmexec.com/pharmexec/Agency+Insight/Finding-that-Perfect-Pitch/ArticleStandard/Article/detail/757965?ref=25 A good creative brief takes raw information and makes it come alive. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757965null XML http://www.pharmexec.com/pharmexec/Regulatory/Tightening-the-Compliance-Net/ArticleStandard/Article/detail/757955?ref=25 A dissection of the new Sunshine regulations in the Affordable Care Act 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757955null XML http://www.pharmexec.com/pharmexec/Product+Spotlight/Brand-of-the-Year-Humira/ArticleStandard/Article/detail/757392?ref=25 Rich data on the clinical side, combined with flexible marketing and outreach to payers, have pushed Humira to the top ranks of powerhouse drugs... 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052012/757392/Humira-ProdShot-small_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Country+Reports/Japanese-Knowledge-Brought-to-Brazil/ArticleStandard/Article/detail/757961?ref=25 Astellas makes its presence felt in Brazil. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757961null XML http://www.pharmexec.com/pharmexec/Strategy/Sales-Force-Survey-Still-Too-Much-Business-as-Usua/ArticleStandard/Article/detail/757953?ref=25 In the global battle for market share, the ability to adapt and mobilize your human assets around a responsive commercial model is a key variable of success. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757953/sales-survey_flash_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/From+the+Editor/Brand-Success-Its-Not-Serendipity/ArticleStandard/Article/detail/757964?ref=25 A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757964/W_Looney-for-web_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757964null XML http://www.pharmexec.com/pharmexec/Country+Reports/How-Do-You-Make-a-Hormone/ArticleStandard/Article/detail/757968?ref=25 French-based Besins is a relatively new entrant to the Brazilian pharma market. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757968null XML http://www.pharmexec.com/pharmexec/Strategy/Prizing-the-Eye--Brent-Saunders-CEO-Bausch---Lomb/ArticleStandard/Article/detail/757967?ref=25 Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company". 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757967/Brent-Saunder-176_flash.jpg XML http://www.pharmexec.com/pharmexec/Country+Reports/Trying-Trials-at-GC-2/ArticleStandard/Article/detail/757962?ref=25 Brazil's clinical trial research is the country's backbone. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757962null XML http://www.pharmexec.com/pharmexec/Back+Page/Industry-Trees-are-Falling-But-is-FDA-Around-to-He/ArticleStandard/Article/detail/757971?ref=25 Experts weigh in on FDA's long-awaited social media guidelines. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757971null XML http://www.pharmexec.com/pharmexec/Country+Reports/Brazil-Report-A-Bold-Player-Blooms/ArticleStandard/Article/detail/757959?ref=25 Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757959null XML http://www.pharmexec.com/pharmexec/Whitepaper/Customer-Intimacy-The-Pharma-Challenge/ArticleStandard/Article/detail/723160?ref=25 Industry leaders weigh in on how pharmaceutical companies can become more relevant to their trifecta of customers: physicians, payers and patients. Read about the strategies pharmaceutical companies are using to cultivate relationships, not just sales – and to become trusted information resources, not just purveyors of products. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212011/723160null REMOTE http://www.pharmexec.com/pharmexec/Washington+Report/Costs-and-Benefits-of-Health-Reform/ArticleStandard/Article/detail/757960?ref=25 Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices? 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757960null XML http://www.pharmexec.com/pharmexec/Whitepaper/SASreg-for-Marketing-Strategy-and-Planning/ArticleStandard/Article/detail/723159?ref=25 Learn how life sciences companies can get more performance from their marketing dollars. This paper shows the way by first detailing the challenges that companies must overcome to shift their marketing strategies to emphasize efficiency and ROI. Then, it presents six key benefits of adopting an analytical approach to marketing. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212011/723159null REMOTE http://www.pharmexec.com/pharmexec/ClearTrial---Increasing-Planning-Efficiency-in-Cli/ArticleStandard/Article/detail/756928?ref=25 ClearTrial - Increasing Planning Efficiency in Clinical Development 2012-01-24T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042012/756928null HTML http://www.pharmexec.com/pharmexec/Whitepaper/UPS-Survey-Unveils-Healthcare-Supply-Chain-Trends/ArticleStandard/Article/detail/743228?ref=25 The 2011 UPS “Pain in the (Supply) Chain” survey explores top business and supply chain concerns at pharmaceutical, biotech and medical device companies worldwide. Findings show changes in healthcare legislation, reform and intellectual property protection are major concerns as the industry’s pace accelerates globally. 2012-01-23T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412011/743228null REMOTE http://www.pharmexec.com/pharmexec/Cloud-Based-Customer-Management-When-Efficiency-Re/ArticleStandard/Article/detail/756688?ref=25 Cloud-Based Customer Management: When Efficiency Reigns, Opportunities Pour 2012-01-19T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756688/John-Kelly-PfizerWEB_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756688null HTML http://www.pharmexec.com/pharmexec/Whitepaper/Physician-Targeting-and-Segmentation-Report/ArticleStandard/Article/detail/755294?ref=25 This report from the OneKey, Powered by SK&A database provides a valuable reference table with all the counts of all U.S. physicians by state and 95 medical specialties. Use this report to strategize for personal and non-personal promotions by understanding where your primary targets are located. The report, updated twice per year, also ranks the top 20 specialty areas by number of practicing physicians. 2012-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022012/755294null REMOTE http://www.pharmexec.com/pharmexec/SKampA---Physician-Targeting-and-Segmentation-Repo/ArticleStandard/Article/detail/755293?ref=25 SK&A - Physician Targeting and Segmentation Report 2012-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022012/755293null HTML http://www.pharmexec.com/pharmexec/Meeting-Global-Patient-Demand-for-Access-to-Medici/ArticleStandard/Article/detail/756689?ref=25 Meeting Global Patient Demand for Access to Medicines Prior to Approval and Launch 2012-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756689/John-Kelly-PfizerWEB_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756689null HTML http://www.pharmexec.com/pharmexec/Country+Reports/Financing-RampD-Through-a-Range-of-Consumer-Produc/ArticleStandard/Article/detail/755088?ref=25 The use and study of DDW by the Hungarian medical community 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755088null XML http://www.pharmexec.com/pharmexec/Noteworthy/European-Pharma-to-Surge-Ahead-Of-US/ArticleStandard/Article/detail/757477?ref=25 The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052012/757477/growth_economy_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052012/757477null XML http://www.pharmexec.com/pharmexec/Technology/iPad-Apps-Are-You-Content-with-your-Content/ArticleStandard/Article/detail/755081?ref=25 Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755081/ipad-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755081/ipad-small_flash.jpg XML http://www.pharmexec.com/pharmexec/Regulatory/Essential-Questions-for-Essential-Benefits/ArticleStandard/Article/detail/755093?ref=25 A key consideration under the Affordable Care Act is how states select plans for drug coverage. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755093null XML http://www.pharmexec.com/pharmexec/Country+Reports/Hungary-Report-Redefining-Sustainability/ArticleStandard/Article/detail/755085?ref=25 Hungary's high-quality infrsatructure, highly skilled labor force, and central geographic location have turned the country into an attractive destination for investment. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755085null XML http://www.pharmexec.com/pharmexec/Back+Page/Top-Medical-Innovations-2012/ArticleStandard/Article/detail/755083?ref=25 A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755083/medical-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755083null XML http://www.pharmexec.com/pharmexec/Legal/Compliance-Getting-Those-Ducks-in-a-Row/ArticleStandard/Article/detail/755089?ref=25 Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755089/Ducks-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755089null XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Innovation-Why-is-Pharma-Scared-to-Death/ArticleStandard/Article/detail/755086?ref=25 It's a disturbing irony: In an industry whose entire economic value is founded on its ability to innovate, why is there so much discomfort with the risk required for innovation. Where did the courage to innovate go? 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755086/anxiety2_flash.jpg XML http://www.pharmexec.com/pharmexec/Country+Reports/Capitalizing-on-Centralization/ArticleStandard/Article/detail/755082?ref=25 A quick chat with CMO of Assign Group Dr. Kata Mazalin 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755082null XML http://www.pharmexec.com/pharmexec/Noteworthy/Emerging-Markets-Bridging-the-Cancer-Divide/ArticleStandard/Article/detail/755090?ref=25 William Looney looks at how Big Pharma is attempting to bridge the emerging markets' widening cancer divide. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755090/Footbridge-asia-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755090/Footbridge-asia_flash.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Heres-to-a-Happier-New-Year/ArticleStandard/Article/detail/755080?ref=25 A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755080null XML http://www.pharmexec.com/pharmexec/Noteworthy/The-Pro-Patient-Cometh/ArticleStandard/Article/detail/755084?ref=25 How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all? 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755084/patient-jump-120x90_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Washington+Report/New-Year-New-Issues/ArticleStandard/Article/detail/755092?ref=25 Look for action in 2012 on drug access, shortages, innovation, and transparency. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755092null XML http://www.pharmexec.com/pharmexec/Global/Pharma-2012-Hard-Times-Before-the-Harvest/ArticleStandard/Article/detail/755087?ref=25 The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755087/Harvest-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Commentary/Copay-Cards-and-Coupons-Letting-the-Facts-Get-in-t/ArticleStandard/Article/detail/755091?ref=25 Mason Tenaglia offers empirical defense of coupons and copay offset programs. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755091/tenaglia_mason_1481_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755091null XML http://www.pharmexec.com/pharmexec/Inside-the-Mind-of-The-CEO/ArticleStandard/Article/detail/752550?ref=25 2011-12-14T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752550null PDF http://www.pharmexec.com/pharmexec/Country+Reports/DW-Languages-ndash-Rebuilding-the-UK-Word-by-Word/ArticleStandard/Article/detail/752382?ref=25 The pharmaceutical industry in Britain is a key sesctor in the full economic recovery of the country 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752382null XML http://www.pharmexec.com/pharmexec/Global/Chinas-Future-in-Bioscience/ArticleStandard/Article/detail/752337?ref=25 Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse? 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752337/china_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752337null XML http://www.pharmexec.com/pharmexec/Noteworthy/Employment-Outlook-Brightens/ArticleStandard/Article/detail/757476?ref=25 The economic and financial crisis rumbles on, but data from Pharmaceutical Technology's 2011 annual employment survey shows a positive outlook for 2012. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052012/757476/outlook_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052012/757476null HTML http://www.pharmexec.com/pharmexec/Country+Reports/UK-Report-Keep-Calm-and-Carry-On--Differently/ArticleStandard/Article/detail/752379?ref=25 Even as the global economic roller coaster affects one of the country's dearest public institutions—the National Health Service—there is still reason for optimism in these times of austerity 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752379null XML http://www.pharmexec.com/pharmexec/Deals/Pharm-Execs-2012-Pipeline-Report/ArticleStandard/Article/detail/752361?ref=25 It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752361/pipeline-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Direct+to+Consumer/Give-It-to-Me-Straight/ArticleStandard/Article/detail/752372?ref=25 Patients want to take a more active role in treatment decisions. Drug facts boxes in DTC ads represent a crucial element of informed consent. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752372null XML http://www.pharmexec.com/pharmexec/Back+Page/Artists-amp-Ad-Men/ArticleStandard/Article/detail/752374?ref=25 Some of the most creative and influential graphic designers and illustrators did time in pharma marketing. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752374null XML http://www.pharmexec.com/pharmexec/Leadership+Column/RaQualias-New-Spin-on-the-Startup/ArticleStandard/Article/detail/752341?ref=25 Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752341/Nagahisa_interior2_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752341null XML http://www.pharmexec.com/pharmexec/Global+Report/Europes-Transparency-Directive-Revisited/ArticleStandard/Article/detail/752328?ref=25 The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver? 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752328null XML http://www.pharmexec.com/pharmexec/From+the+Editor/Was-2011-the-End-of-the-Beginning/ArticleStandard/Article/detail/752324?ref=25 The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752324/W_Looney-for-web_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752324null XML http://www.pharmexec.com/pharmexec/Leadership+Column/The-Medicines-Adherence-Challenge/ArticleStandard/Article/detail/752368?ref=25 Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma — but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752368/round-table-thumb21466761_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752368null XML http://www.pharmexec.com/pharmexec/Country+Reports/The-Word-on-UK-Biotech/ArticleStandard/Article/detail/752384?ref=25 GM's and investors find consensus in identifying innovation and productivity emerging from academia and small startups 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752384null XML http://www.pharmexec.com/pharmexec/Strategy/The-Payoff-for-Payers/ArticleStandard/Article/detail/752333?ref=25 Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752333null XML http://www.pharmexec.com/pharmexec/Washington+Report/FDA-Gets-a-New-Look/ArticleStandard/Article/detail/752326?ref=25 Agency expansion and globalization promote innovation, collaboration, and organizational changes 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752326null XML http://www.pharmexec.com/pharmexec/Advertise/revised2012pharmexeconlineratecard/ArticleStandard/Article/detail/747284?ref=25 Revised PharmExec 21012 Rate Card 2011-11-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747284null PDF http://www.pharmexec.com/pharmexec/Pharm-Exec-Global-Digest-2012/ArticleStandard/Article/detail/747302?ref=25 PhamExec Global Digest 2012 2011-11-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747302null PDF http://www.pharmexec.com/pharmexec/june2011bpastatement/ArticleStandard/Article/detail/747196?ref=25 June 2011 BPA Statement 2011-11-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747196null PDF http://www.pharmexec.com/pharmexec/Invar/ArticleStandard/Article/detail/747600?ref=25 Foreign player? Choose a local partner 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747600null XML http://www.pharmexec.com/pharmexec/Novo-Nordisk/ArticleStandard/Article/detail/747599?ref=25 The triple bottom line 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747599null XML http://www.pharmexec.com/pharmexec/Back+Page/Fostering-a-Legacy-of-Leadership/ArticleStandard/Article/detail/747587?ref=25 Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747587null XML http://www.pharmexec.com/pharmexec/Strategy/Clinical-Trial-Issues-Not-Just-Black-and-White/ArticleStandard/Article/detail/747594?ref=25 The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747594null XML http://www.pharmexec.com/pharmexec/Agency+Insight/Agency-Assignments-Managing-the-Hidden-Costs/ArticleStandard/Article/detail/747596?ref=25 Saving the agency/client relationship begins first with the people involved and defining accountability on both sides 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747596/piggy-bank-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747596null XML http://www.pharmexec.com/pharmexec/The-Road-from-No-20/ArticleStandard/Article/detail/747589?ref=25 How is the world's dedicated pharma leader going to improve its positioning in Russia? Pfizer's country manager Christian Holmer comments. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747589null XML http://www.pharmexec.com/pharmexec/PEGD-Media-Kit-2012/ArticleStandard/Article/detail/750458?ref=25 PEGD Media Kit 2012 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492011/750458null PDF http://www.pharmexec.com/pharmexec/Professional+Marketing/Pharmas-Visit-to-the-Plastic-Surgeon/ArticleStandard/Article/detail/747606?ref=25 The bigger the company, the thicker the sclerosis, the more they need to suck out the fat 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747606null XML http://www.pharmexec.com/pharmexec/Global+Report/Does-a-German-Launch-Make-Sense/ArticleStandard/Article/detail/747588?ref=25 Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market? 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747588/Germany-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747588null XML http://www.pharmexec.com/pharmexec/Euroservice/ArticleStandard/Article/detail/747604?ref=25 Know your strengths, then expand 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747604null XML http://www.pharmexec.com/pharmexec/Back+Page/Prix-Galien-USA-2011/ArticleStandard/Article/detail/747592?ref=25 A celebration of achievement 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747592null XML http://www.pharmexec.com/pharmexec/From+the+Editor/RampD-Costs-Its-Industrys-Problem/ArticleStandard/Article/detail/747602?ref=25 If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747602null XML http://www.pharmexec.com/pharmexec/Washington+Report/The-Drug-Shortages-Struggle/ArticleStandard/Article/detail/747603?ref=25 Clamor for critical therapies prompts probes of prices, production practices. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747603null XML http://www.pharmexec.com/pharmexec/R%26D/The-Pharma-Revolution-Recalibrated/ArticleStandard/Article/detail/747598?ref=25 Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747598/light-bulb_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Europe-Tackles-Advertising-in-Disguise-Fears/ArticleStandard/Article/detail/747601?ref=25 The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay? 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747601null XML http://www.pharmexec.com/pharmexec/Articles/The-Rx-Clubs-25th-Anniversary-Show/ArticleStandard/Article/detail/749539?ref=25 Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year? 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472011/749539/Rx-club-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Five-Years/ArticleStandard/Article/detail/747605?ref=25 Five years of legislation in the Russian pharmaceutical industry 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747605null XML http://www.pharmexec.com/pharmexec/Regulatory/Spotlight-on-OTCs/ArticleStandard/Article/detail/747591?ref=25 With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747591null XML http://www.pharmexec.com/pharmexec/Whitepaper/Improving-Clinical-Operations-with-Digital-Signatu/ArticleStandard/Article/detail/746356?ref=25 The majority of large CROs and Pharmas are using digital signatures to speed clinical site initiation, reduce site monitoring reporting costs, and improve audit efficiency. See how digital signatures enable these benefits and others by allowing key players in the clinical ecosystem (site personnel, IRBs, CROs, sponsors) to electronically sign and submit reports and other documents. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442011/746356null REMOTE http://www.pharmexec.com/pharmexec/Plant-Management/ArticleStandard/Article/detail/747593?ref=25 We ask three managers building Greenfield plants to rationalize and defend their decisions 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747593null XML http://www.pharmexec.com/pharmexec/Materia-Medica/ArticleStandard/Article/detail/747590?ref=25 The new idea 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747590null XML http://www.pharmexec.com/pharmexec/Russia-Report-Build-and-Create-The-Reinvention-of-/ArticleStandard/Article/detail/747595?ref=25 Russia had been a country in flux—monetary crises, corruption scandals, oil surpluses, etc. But no multinational should be scared off by the market anymore, not with its economy on the verge of breaking out. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747595null XML http://www.pharmexec.com/pharmexec/Europe+Features/Strategic-Acquisition-A-CEOs-View/ArticleStandard/Article/detail/746465?ref=25 Richard Pops, Chief Executive Officer of Alkermes, explains how the company has established itself as a global, Irish-based firm. 2011-10-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/746465null HTML http://www.pharmexec.com/pharmexec/SAS---SASreg-for-Marketing-Strategy-and-Planning/ArticleStandard/Article/detail/745801?ref=25 SAS - SAS® for Marketing Strategy and Planning 2011-10-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442011/745801null HTML http://www.pharmexec.com/pharmexec/Invitation-Application-for-Pharma-and-Biotech-Indu/ArticleStandard/Article/detail/745815?ref=25 Invitation Application for Pharma and Biotech Industry Executives: 2011-10-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442011/745815null HTML http://www.pharmexec.com/pharmexec/Europe+News/GxP-Cloud-mdash-Business-Enablement-for-Life-Scien/ArticleStandard/Article/detail/743615?ref=25 GxP Cloud — business enablement for Life Sciences 2011-10-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/743615null HTML http://www.pharmexec.com/pharmexec/UPS-Survey-Unveils-Healthcare-Supply-Chain-Trends/ArticleStandard/Article/detail/743227?ref=25 UPS Survey Unveils Healthcare Supply Chain Trends 2011-10-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412011/743227null HTML http://www.pharmexec.com/pharmexec/Marck-McLellan-An-A-for-Advancing-Expectations/ArticleStandard/Article/detail/744342?ref=25 Marck McClellan, MD, Director, Engelberg Center for Health Reform, Brookings Institute 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744342null XML http://www.pharmexec.com/pharmexec/Fernand-Sauer-The-Essentialmdashand-Effectivemdash/ArticleStandard/Article/detail/744332?ref=25 Fernand Sauer, First Director General, European Medicines Agency 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744332null XML http://www.pharmexec.com/pharmexec/Global+Report/Emerging-MarketsThe-Myths-and-Traps/ArticleStandard/Article/detail/744345?ref=25 Success in the emerging markets depends significantly on navigating the myths and mental traps. 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744345/mousetrap-web-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Back+Page/Three-Decades-of-Politics-and-Pop-Culture--on-Drug/ArticleStandard/Article/detail/744341?ref=25 Three Decades of Politics and Pop Culture ... on Drugs 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744341null XML http://www.pharmexec.com/pharmexec/PE-Media-Kit-2012/ArticleStandard/Article/detail/742436?ref=25 media kit 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412011/742436null PDF http://www.pharmexec.com/pharmexec/Francis-Collins-Guiding-a-Revolution-in-Science/ArticleStandard/Article/detail/744350?ref=25 Francis Collins, MD, PhD, Director, National Institutes of Health 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744350null XML http://www.pharmexec.com/pharmexec/Partnering-with-the-New-Players/ArticleStandard/Article/detail/744318?ref=25 Carlos Morel, MD, Director for Technical Development in Health, Oswaldo Cruz Foundation 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744318null XML http://www.pharmexec.com/pharmexec/Productivity-Reputation-are-Keys-to-Global-Leaders/ArticleStandard/Article/detail/744351?ref=25 Yasuchika Hasegawa, President & CEO, Takeda Pharmaceutical Co. 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744351null XML http://www.pharmexec.com/pharmexec/Current+Issue/Inside-the-Mind-of-the-CEO/ArticleStandard/Article/detail/744338?ref=25 Pharm Exec sits down with Steve Collis, CEO of AmerisourceBergen to discuss his agenda for retooling the drug distribution giant. 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744338/mind-of-CEO_thumb_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744338null XML